Cancure
  • Home
  • About
    • Vision
    • Board & Management
    • Scientific Advisors
  • Cancer
    • Current Treatments
    • Market
  • Therapies
    • Genvax – lead candidate CNC118
    • Galectin – lead candidate CNC225
    • Mitocans – lead candidate CNC332
    • Combination Therapy
    • Genvax vs. CAR-T
    • Development Program
    • References
  • Investors
    • Investors Snapshot
    • News
    • Public Documents
  • Contact
  • Glossary of Terms
  • Search
  • Menu Menu
Cancer Treatments
Galectin
Mitocans
Mitocans

NousCom receives $49M to trial off-the-shelf cancer vaccine

http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png 0 0 admin http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png admin2017-11-09 11:00:212017-11-09 11:00:21NousCom receives $49M to trial off-the-shelf cancer vaccine

AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans

http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png 0 0 admin http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png admin2017-11-01 13:09:192017-11-01 13:10:55AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans

Incyte pays MacroGenics $150M for PD-1 inhibitor

http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png 0 0 admin http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png admin2017-10-26 09:04:412017-11-01 09:15:40Incyte pays MacroGenics $150M for PD-1 inhibitor

Gilead buys CAR-T developer Kite Pharma for $12B

http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png 0 0 admin http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png admin2017-08-29 08:58:062017-11-01 09:35:19Gilead buys CAR-T developer Kite Pharma for $12B

Bone marrow cancer and immuno-oncology research agreement

http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png 0 0 admin http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png admin2017-07-27 16:00:492017-11-01 09:17:14Bone marrow cancer and immuno-oncology research agreement

Servier, Pieris launch up to $1.8B immuno-oncology alliance

http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png 0 0 admin http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png admin2017-01-05 16:00:162017-11-01 09:18:40Servier, Pieris launch up to $1.8B immuno-oncology alliance

Roche bets up to $1B on Blueprint’s immunomodulation platform

http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png 0 0 admin http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png admin2016-03-16 08:45:312017-11-01 09:39:35Roche bets up to $1B on Blueprint’s immunomodulation platform

Lilly signs a $1B deal to deepen its oncology ties with China’s Innovent

http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png 0 0 admin http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png admin2015-10-27 03:58:442021-08-16 22:02:22Lilly signs a $1B deal to deepen its oncology ties with China’s Innovent

Novartis inks a string of deals to widen its immuno-oncology arsenal

http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png 0 0 admin http://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png admin2015-10-27 03:58:262021-08-16 22:02:23Novartis inks a string of deals to widen its immuno-oncology arsenal
PreviousNext

“Cancure’s mission is to develop breakthrough drugs that push the limits of anti-cancer response rates, and hasten the evolution of cancer treatments into cancer cures. ”

Cancure is a biopharmaceutical company founded in 2012, with the aim of investing in therapies capable of countering several major diseases afflicting society today.

Cancure has developed a suite of breakthrough oncology therapies, which employ innovative methods to enhance the body’s anti-cancer immune response, or kill cancer cells by exploiting novel targets within them. These revolutionary therapies are ideally positioned in the emerging fields of immuno-oncology, combination therapies and mitochondrial biology.

Cancure is developing these therapies into marketable drugs that push the limits of anti-cancer response rates and hasten the evolution of cancer treatments into cancer cures.

Genvax

GENVAX

Galectin

GALECTIN INHIBITORS

Mitocans

MITOCANS

NEWS

  • NousCom receives $49M to trial off-the-shelf cancer vaccine
  • AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans
  • Incyte pays MacroGenics $150M for PD-1 inhibitor
  • Gilead buys CAR-T developer Kite Pharma for $12B

Contact

Mr Craig Miles
craig@cancure.com
+61 (0) 408 778 797
PO Box 1177, Broadbeach,
Queensland, Australia 4218

Copyright © 2021 All rights reserved.
  • Twitter
  • Dribbble
Scroll to top